Johnson & Johnson (NYSE:JNJ) Stock Holdings Lifted by Hohimer Wealth Management LLC

Hohimer Wealth Management LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 12.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,911 shares of the company's stock after purchasing an additional 2,481 shares during the period. Hohimer Wealth Management LLC's holdings in Johnson & Johnson were worth $3,634,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of JNJ. Norges Bank bought a new stake in shares of Johnson & Johnson in the fourth quarter worth about $4,390,037,000. GAMMA Investing LLC raised its stake in Johnson & Johnson by 24,450.4% during the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after buying an additional 7,185,977 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after buying an additional 4,842,582 shares during the last quarter. Janus Henderson Group PLC raised its stake in Johnson & Johnson by 134.5% during the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock valued at $1,149,536,000 after buying an additional 4,559,147 shares during the last quarter. Finally, Northern Trust Corp increased its stake in shares of Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after purchasing an additional 3,363,235 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 6.4%

Shares of Johnson & Johnson stock traded up $10.00 on Wednesday, reaching $165.17. 12,909,325 shares of the company were exchanged, compared to its average volume of 8,108,093. The stock has a fifty day moving average price of $153.80 and a 200-day moving average price of $154.64. The firm has a market capitalization of $397.41 billion, a price-to-earnings ratio of 18.38, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period in the previous year, the firm earned $2.82 earnings per share. Johnson & Johnson's revenue for the quarter was up 5.8% compared to the same quarter last year. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.15%. Johnson & Johnson's payout ratio is 57.84%.

Analysts Set New Price Targets

A number of brokerages have issued reports on JNJ. Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 5th. Raymond James Financial dropped their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Finally, Barclays dropped their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $171.00.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.